3rd Edition: Safety and Autoimmune Response to SARS-CoV-2 Vaccination
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".
Deadline for manuscript submissions: 31 August 2026 | Viewed by 1900
Special Issue Editor
Interests: PET/CT; COVID-19; Vaccine; Vaccination
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
COVID-19 remains a public health concern. Vaccination is important to prevent disease. SARS-CoV-2 vaccines are considered highly effective and safe despite several indications of adverse events following immunization. These transient symptoms have been reported to include cerebral venous sinus thrombosis, demyelinating episodes, lymphadenopathy, cognitive decline, and myalgia/arthralgia.
We invite you to contribute your work to this Special Issue titled “Safety and Autoimmune Response to SARS-CoV-2 Vaccination”. This Special Issue aims to publish high-quality reviews, regular research papers, and communications on the safety of the SARS-CoV-2 vaccine in the general population and special groups, proposals of different schedules and their effects on vaccine safety, security of neurological adverse events following immunization, and other aspects that may be proposed.
We look forward to receiving your contributions.
Dr. Minghui Yang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- COVID-19 vaccine
- vaccine efficacy
- vaccine safety
- adverse events following immunization
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
